



ASX ANNOUNCEMENT

Managing Director's AGM Presentation


Sydney, 25 November 2019. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to release an updated Investor Presentation that will be used in part for the Managing Director's AGM presentation.

Key Highlights

- XanaHES trial (20mg Xanamem daily) achieved a robust cognitive efficacy improvement, with results supporting the cortisol hypothesis
- Actinogen's lead compound, Xanamem, demonstrated to be an efficacious, oral, brain penetrant, selective 11 β -HSD1 inhibitor, with a validated novel mechanism of action and strong safety profile
- Next phase of Xanamem's Alzheimer's disease clinical development, expected to target patients with Mild Cognitive Impairment – based on recently completed XanaHES results
- The Company plans to leverage its Xanamem platform technology across multiple other indications, including cognitive impairment associated with schizophrenia, bipolar and diabetes
- Future study parameters being optimised, including dose and dosing regimen following latest trial results. Also exploring potential partnership and collaborative funding opportunities
- Xanamem development is targeting huge unmet medical needs with unsustainable healthcare costs

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Arthur Chan
WE Communications
P: +61 2 9237 2805
E: arthurc@we-worldwide.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company focused on innovative approaches to treating cognitive decline that occurs in chronic neurological and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with multibillion-dollar market potential and material human impact. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is projected to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. In addition, Actinogen is currently planning an expanded clinical development program for Xanamem in cognitive impairment in mood disorders and schizophrenia. In the US alone, the collective economic costs of mood disorders and schizophrenia are estimated to exceed \$550bn, with the burden increasing every year. The cognitive dysfunction associated with these conditions is significantly debilitating for affected patients, with a substantial unmet medical need for novel, improved treatments.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory. The 11 β -HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, mood disorders and schizophrenia.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem 10mg daily in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

About XanaHES

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment are measured as an exploratory efficacy outcome.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.